

---

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549**

**FORM 6-K**

**REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934**

**For the month of November 2018**

Commission File Number: **333-219066**

**Clementia Pharmaceuticals Inc.**  
(Translation of registrant's name into English)

**4150 St Catherine Street West, Suite 550**  
(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.  
Form 20-F  Form 40-F

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

**Note:** Regulation S-T Rule 101(b)(1) only permits the submission in paper of a Form 6-K if submitted solely to provide an attached annual report to security holders.

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):

**Note:** Regulation S-T Rule 101(b)(7) only permits the submission in paper of a Form 6-K if submitted to furnish a report or other document that the registrant foreign private issuer must furnish and make public under the laws of the jurisdiction in which the registrant is incorporated, domiciled or legally organized (the registrant's "home country"), or under the rules of the home country exchange on which the registrant's securities are traded, as long as the report or other document is not a press release, is not required to be and has not been distributed to the registrant's security holders, and, if discussing a material event, has already been the subject of a Form 6-K submission or other Commission filing on EDGAR.

---

The information contained in this Report (including the exhibits hereto) is hereby incorporated by reference into Clementia Pharmaceuticals Inc.'s Registration Statement on Form F-3 (File No. 333-227726).

On November 21, 2018, the Registrant issued a press release, a copy of which is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

(c) [Exhibit 99.1](#). Press release dated November 21, 2018

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

**Clementia Pharmaceuticals Inc.**  
(Registrant)

Date: November 21, 2018

/s/ Steve Forte  
Steve Forte  
Chief Financial Officer

## Clementia to Present at the Evercore ISI HealthCONx Conference

MONTREAL, Nov. 21, 2018 (GLOBE NEWSWIRE) -- **Clementia Pharmaceuticals Inc.** (Nasdaq: CMTA), a clinical-stage biopharmaceutical company innovating treatments for people with ultra-rare bone disorders and other diseases, today announced that Clarissa Desjardins, Ph.D., chief executive officer and founder of Clementia, will present at the Evercore ISI HealthCONx Conference on Wednesday, November 28, 2018 at 10:15 a.m. ET in Boston.

A webcast of the presentation will be available in the Investor Relations section of the company's website at [www.clementiapharma.com](http://www.clementiapharma.com). The replay of the webcast will be available for 30 days following the call.

### **About Clementia Pharmaceuticals Inc.**

Clementia is a clinical-stage company innovating treatments for people with ultra-rare bone disorders and other diseases with high medical need. The company is preparing for a 2019 NDA submission to the FDA to seek approval of its lead product candidate, palovarotene, a novel RAR $\gamma$  agonist, for the prevention of heterotopic ossification (HO) associated with flare up symptoms in patients with fibrodysplasia ossificans progressiva (FOP). The ongoing Phase 3 MOVE Trial is evaluating an additional dosing regimen of palovarotene for the treatment of FOP. Palovarotene is also in a Phase 2 trial, the MO-Ped Trial, for the treatment of multiple osteochondromas (MO, also known as multiple hereditary exostoses, or MHE). In addition, Clementia has commenced a Phase 1 trial for an eye drop formulation of palovarotene for the potential treatment of dry eye disease and is also investigating other conditions that may benefit from RAR $\gamma$  therapy. For more information, please visit [www.clementiapharma.com](http://www.clementiapharma.com) and connect with us on Twitter [@ClementiaPharma](https://twitter.com/ClementiaPharma).

### **Investor/Media Contact:**

Joseph Walewicz  
Clementia Pharmaceuticals Inc.  
+1-514-940-1080

Chelcie Lister  
THRUST Strategic Communications  
+1-910-777-3049